ERAS
Erasca, Inc.
$17.63
+3.22%
2026-08-21
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-31.59
EPS (TTM)
$-0.95
ROE
-78.2%
Profit Margin
0.0%
Debt/Equity
12.36
Price/Book
14.52
Beta
0.65
Market Cap
$6.43B
Avg Volume (10D)
3.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$21.60
60D Low
$11.81
Avg Volume
4.7M
Latest Close
$17.63
Get breakout alerts for ERAS
Sign up for Breakout Scanner to receive daily notifications when ERAS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Erasca, Inc. (ERAS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ERAS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ERAS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.